Meagan Parrish from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting		Pharma’s ‘it’ therapy — a new drug class gaining steam - 4 days ago Is anyone taking the world’s priciest drugs? - 9 days ago What pharma has learned from AI - about 1 month ago Neuro drugs are still faltering, despite rising investment - about 1 month ago Bird flu puts BARDA back in the spotlight - about 2 months ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - about 2 months ago Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - about 2 months ago Up-and-comers look for an edge in the bustling ADC field - 2 months ago Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll - 3 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 3 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 3 months ago Where competition is heating up in pharma - 4 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 4 months ago Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma - 4 months ago As BMS announces major cuts, its Karuna deal looks poised to drive growth - 4 months ago 3 big recent trial flops - 5 months ago Viral return: 3 U.S. cases concerning experts - 5 months ago The pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle - 6 months ago GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that. - 6 months ago After Amylyx drug failure, what’s next for ALS? - 6 months ago As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients - 6 months ago Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D - 6 months ago Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category - 6 months ago Behind a big-name rare disease biotech, an exec draws from personal experience - 6 months ago Astellas’ science chief on the leap into new technologies - 7 months ago Could Novo, Lilly become first trillion-dollar healthcare companies? - 7 months ago ‘1 plus 1 equals 3’ — the co-CEO model in pharma - 8 months ago The biggest questions hanging over pharma in 2024 - 8 months ago Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - 8 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 8 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 8 months ago 10 of our most read articles in 2023 - 9 months ago A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19 - 9 months ago The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing. - 9 months ago 3 standout digital innovations in pharma this year - 9 months ago A startling drop in U.S. life expectancy — and how pharma could help turn the tide - 10 months ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - 10 months ago PharmaVoice 100s: Entrepreneurs - 10 months ago The 2023 Red Jacket honorees - 11 months ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - 11 months ago PharmaVoice 100s: Clinical trial gurus - 11 months ago 5 minutes with — IDEA Pharma’s Mike Rea - 11 months ago 3 recent FDA adcomm rejections — and why they matter - 11 months ago The PharmaVoice 100: Standout execs - 12 months ago